Vascular tone & cAMP phosphodiesterase in angioplasty
Vascular tone & cAMP phosphodiesterase in angioplasty
批准号:
6922843
负责人:
JOHN QUILLEY
金额:
$31.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2007-08-31
关键词:
3&apos5&apos cyclic nucleotide phosphodiesteraseaortabiological signal transductioncardiovascular injurycell proliferationcyclic AMPenzyme activityenzyme induction /repressionimmunocytochemistryin situ hybridizationintraluminal angioplastyisozymeslaboratory ratphosphodiesterase inhibitorsprotein kinase Avascular endotheliumvascular smooth musclevasodilatorsvasomotionvasospasm
中文摘要
超出所提供的空间。大鼠主动脉球囊导管去内皮化(BAL)后内膜增厚,平滑肌细胞(SMC)增殖和迁移增强。最近的研究表明,通过特异性抑制cAMP磷酸二酯酶PDE 3和/或PDE 4激活cAMP依赖性蛋白激酶(PKA)可减少血管成形术后SMC的增殖/迁移和病变。除了SMC生长的变化外,收缩性也可能受到损伤的影响。总体假设:BAL导致SMC和血管壁相关炎性细胞中特异性cAMP PDE的表达和活性增强,然后影响SMC环核苷酸水平、蛋白磷酸化和收缩性。该项目将首先确定哪些高亲和力,cAMP选择性PDE 3和PDE 4亚型在BAL损伤的大鼠主动脉或生长因子刺激的大鼠主动脉SMC中上调,而随后的目标是评估PDE上调对cAMP依赖性磷酸化,血管收缩性和细胞位置的影响。目的1A:确定体内BAL后PDE 3A/3B和PDE 4A/4 B/4D基因蛋白表达的时间过程。主动脉中膜SMC的初步数据显示,BAL与PDE 4 BmRNA的双相增加相关,其他基因(PDE 3A,4D)的变化较小(PDE 3B)或无变化。目的:观察PDE 4 B、PDE 4D和PDE 3A蛋白剪接变异体在血清、PDGF-BB和bFGF刺激RASMC中的表达。目标2A:确定PDE抑制剂增强PKA活性的时间进程,或SMC中血管舒张剂敏感底物VASP的PKA依赖性磷酸化。这些细胞内cAMP的指标将用于确定抑制BAL中过表达的PDE 3/4是否恢复或增强β激动剂和毛喉素依赖性激活。目的2B:确定体外PDE 3/4上调对VASP磷酸化和PKA活性的影响。目的3:用各种血管扩张剂加/减PDE抑制剂表征损伤后24小时和1-2周时BAL主动脉的收缩性。目标4:用免疫组化和原位杂交方法检测BAL后24小时和7- 14天主动脉PDE表达的细胞特异性,推测PDE 3/4的增加可减少cAMP和cGMP水平升高药物引起的血管舒张。PDE的过度表达促进血管痉挛,而血管痉挛可能影响血管壁的重塑,特异性PDE的上调是对损伤的重要反应,可能作为再狭窄和高血压的治疗靶点。 性能现场=
英文摘要
EXCEED THE SPACE PROVIDED. Enhanced smooth muscle cell (SMC) proliferation and migration account for intitnal thickeningwhich follows balloon catheter de-endothelialization(BAL) of rat aorta. Recent studies show activation of cAMP-dependent protein kinase (PKA) by specific inhibition of cAMP phosphodiesterases PDE3 and/or PDE4 reduces SMC proliferation/ migration and lesions after angioplasty. In addition to changes in SMC growth, contractility may be affected by injury. Overall hypothesis: BAL leads to enhanced expression and activity of specific cAMP PDEs in both SMC and vessel wall-associated inflammatory cells, which then affects SMC cyclic nucleotide levels, protein phosphorylation and contractility. The project will first identify which high affinity, cAMP-selective PDE3 and PDE4 isoforms are upregul- ated in the BAL-injured rat aorta or growth factor-stimulated rat aortic SMC, while later aims assess the impact of PDE upregulationon cAMP-dependent phosphorylation,vessel contractility, and cellular locale. Aim 1 A: Determine the time course of protein expression for PDE3A/3B and PDE4A/4B/4D genes followingBAL in vivo. Pilot data for aortic medial SMC show that BAL is associated with biphasic increases in PDE4BimRNA, and smaller (PDE3B) or no changes in other genes (PDE3A, 4D). Aim IB: To determine the time course of PDE4B, PDE4D and PDE3A protein splice variants in RASMC stimulatedwith serum, PDGF-BB or bFGF. Aim 2A: Determine the time course for PDE inhibitor enhancementof PKA activity, or PKA-dependent phosphorylation of a vasodilator-sensitive substrate VASP in SMC. These indicesof intracellular cAMP will be used to determine if inhibition of overexpressed PDE3/4 in BAL restores or enhances beta-agonist and forskolin-dependent activation. Aim 2B: Determine the impact of PDE3/4 upregulation in vitro on VASP phosphorylation and PKA activity. Aim 3: Characterize contractility of the BAL aorta at 24 hr and 1-2 weeks after injury with various vasodilators plus/minus PDE inhibitors. Aim 4: Identify at 24 hr and 7- 14 days after BAL the aortic cellular specificityof PDE expression by immunohistochemistry and in situ hybridizati- on. The increase in PDE3/4 is predicted to reduce vasorelaxation produced by agents which increase cAMP and cGMP levels. PDE overexpression favors vasospasm, which may affect vessel wall remodeling.Upregulation of specific PDEs represents an importantresponse to injury that may serve as a therapeutictarget in restenosis and hypertension. PERFORMANCE SITE ========================================Section End===========================================
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.ejphar.2008.05.016
发表时间:
2008-08
期刊:
European journal of pharmacology
影响因子:
5
作者:
[Hong Zhao;Qizhi Guan;Carolyn J. Smith;J. Quilley]
通讯作者:
Hong Zhao;Qizhi Guan;Carolyn J. Smith;J. Quilley
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
磷酸二酯酶 PDE-3/PDE-4 特异性抑制剂对球囊血管成形术后血管收缩和 cAMP 依赖性血管舒张的不同影响。
DOI:
10.1152/ajpheart.00419.2006
发表时间:
2007
期刊:
American journal of physiology. Heart and circulatory physiology
影响因子:
--
作者:
[Zhao,Hong, Quilley,John, Montrose,DavidC, Rajagopalan,Swarna, Guan,Qizhi, Smith,CarolynJ]
通讯作者:
Smith,CarolynJ
Effect of tempol on renal cyclooxygenase expression and activity in experimental diabetes in the rat.
tempol 对实验性糖尿病大鼠肾环氧合酶表达和活性的影响。
DOI:
10.1124/jpet.104.076927
发表时间:
2005
期刊:
The Journal of pharmacology and experimental therapeutics.
影响因子:
--
作者:
[Li,Jing, Chen,Yu-Jung, Quilley,John]
通讯作者:
Quilley,John
Vascular tone & cAMP phosphodiesterase in angioplasty
-
批准号:6787697
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2002
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:6202240
-
项目类别:
-
资助金额:$24.35万
-
财政年份:1999
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:6109761
-
项目类别:
-
资助金额:$24.35万
-
财政年份:1998
-
负责人:JOHN QUILLEY
-
依托单位:
INTERACTION OF KININS AND CYT P450 IN HYPERTENSION
-
批准号:2459990
-
项目类别:
-
资助金额:$17.39万
-
财政年份:1997
-
负责人:JOHN QUILLEY
-
依托单位:
INTERACTION OF KININS AND CYT P450 IN HYPERTENSION
-
批准号:6322808
-
项目类别:
-
资助金额:$12.23万
-
财政年份:1997
-
负责人:JOHN QUILLEY
-
依托单位:
INTERACTION OF KININS AND CYT P450 IN HYPERTENSION
-
批准号:2750375
-
项目类别:
-
资助金额:$5.85万
-
财政年份:1997
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:6241861
-
项目类别:
-
资助金额:$23.54万
-
财政年份:1997
-
负责人:JOHN QUILLEY
-
依托单位:
INTERACTION OF KININS AND CYT P450 IN HYPERTENSION
-
批准号:2225410
-
项目类别:
-
资助金额:$16.68万
-
财政年份:1996
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:3780460
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
RENAL PROSTAGLANDINS AND HYPERTENSION
-
批准号:3921503
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
ANALYTICAL CORE
-
批准号:4696242
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
ANALYTICAL CORE
-
批准号:3968221
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:5213532
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:--
RENAL PROSTAGLANDINS AND HYPERTENSION
-
批准号:3944365
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:3880252
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
ANALYTICAL CORE
-
批准号:3921505
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
RENAL PROSTAGLANDINS AND HYPERTENSION
-
批准号:3900476
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
ANALYTICAL CORE
-
批准号:3900478
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:3859252
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
VASCULAR CYTOCHROME P450 RELATED ARACHIDONIC ACID PRODUCTS
-
批准号:3758450
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JOHN QUILLEY
-
依托单位:
国内基金
海外基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
-
批准号:81300507
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2013
-
负责人:陈黎
-
依托单位: